Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
3 verified discoveries match your filters.
In laboratory cell-line and mouse studies, a Stanford-engineered small molecule that forces two proteins (the lymphoma oncogene BCL6 and the enzyme CDK9) into physical proximity reprogrammed BCL6 to switch ON…
Primary source cited
Last reviewed
In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective…
Primary source cited
Last reviewed
In the MZL cohort of the single-arm, phase 2 TRANSCEND FL trial, lisocabtagene maraleucel -- a CD19-directed CAR T-cell therapy -- produced an intent-to-treat overall response rate of 84.4% and…
Primary source cited
Last reviewed